Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Vervita K"'
Autor:
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J-Y, De Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, R A
Publikováno v:
Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
Dafni, U, Soo, R A, Peters, S, Tsourti, Z, Zygoura, P, Vervita, K, Han, J Y, de Castro, J, Coate, L, Früh, M, Hashemi, S M S, Nadal, E, Carcereny, E, Sala, M A, Bernabé, R, Provencio, M, Cuffe, S, Roschitzki-Voser, H, Ruepp, B, Rosell, R & Stahel, R A 2022, ' Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis ', ESMO OPEN, vol. 7, no. 3, 100507 . https://doi.org/10.1016/j.esmoop.2022.100507
ESMO OPEN, 7(3):100507. BMJ Publishing Group
BACKGROUND The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in pat